ClinicalTrials.gg

Program

CDK2 Degrader BG-75098

Its studies are led by BeOne Medicines.

Furthest: phase 1, since Nov 6, 20251 company-led study, 1 open or runningNext primary completion: Nov 1, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicines11 open or runningphase 1since Nov 6, 2025Nov 6, 2025Nov 1, 2028phase 1 · NCT07226349

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 6, 2025First study: phase 1 study in Advanced Solid TumorFirst studyNCT07226349 · 105 planned · United States, Australia, China and more

Ahead

  1. Nov 1, 2028Primary completion: phase 1 study in Advanced Solid TumorNCT07226349

TargetBeta

CDK2 →read by rule
“An orally bioavailable chimeric degradation activation compound (CDAC) targeting cyclin-dependent kinase 2 (CDK2), ”NCIt, by rule

Other programs on CDK2

ProgramCompanyFurthest phaseStudies
culmerciclibSino Biopharmaceuticalphase 311
CDK2 Inhibitor INCB123667ruleIncytephase 37
tegtociclibPfizerphase 24
vustanaciclibregor-pharmaceuticals-incphase 23
CDK2 Inhibitor AVZO-021ruleavenzo-therapeutics-incphase 22
CDK2 Inhibitor ECI830Novartisphase 21
CG-7321rulechengdu-cynogen-bio-pharmaceutical-tech-co-ltdphase 11
nkt5097 cdk2rulenikang-therapeutics-incphase 11
ZE94-0605ruleeilean-therapeuticsphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07226349Advanced Solid Tumor · United States, Australia, China and more1RecruitingNov 1, 2028105

How it is read

Names in the registry

  • “BG-75098”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.